COST-EFFECTIVENESS ANALYSIS OF COBLATION TECHNOLOGY VS. MECHANICAL DEBRIDEMENT WITH A SHAVER IN THE TREATMENT OF KNEE CARTILAGE LESIONS- A SPANISH PAYER PERSPECTIVE

被引：1
|
作者：
Adeyemi, A. [1 ]
Nherera, L. [2 ]
Trueman, P. [2 ]
Cano, J. [3 ]
机构：
[1] Smith & Nephew, Andover, MA USA
[2] Smith & Nephew, Watford, Herts, England
[3] Smith & Nephew, Barcelona, Spain
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1050
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMD66
引用
下载
收藏
页码：A584 / A584
页数：1
相关论文
共 50 条
  • [1] COMPARING COSTS AND OUTCOMES BETWEEN COBLATION TECHNOLOGY AND MECHANICAL DEBRIDEMENT IN THE TREATMENT OF KNEE CARTILAGE LESIONS-A COST-EFFECTIVENESS ANALYSIS FROM A US PAYER PERSPECTIVE
    Adeyemi, A.
    Nherera, L.
    Trueman, P.
    Delhougne, G.
    VALUE IN HEALTH, 2017, 20 (09) : A735 - A735
  • [2] Cost-effectiveness analysis of Coblation versus mechanical shaver debridement in patients following knee chondroplasty
    Adeyemi, Ayoade
    Nherera, Leo
    Trueman, Paul
    Ranawat, Anil
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2020, 18 (01)
  • [3] Cost-effectiveness analysis of Coblation versus mechanical shaver debridement in patients following knee chondroplasty
    Ayoade Adeyemi
    Leo Nherera
    Paul Trueman
    Anil Ranawat
    Cost Effectiveness and Resource Allocation, 18
  • [4] COST-EFFECTIVENESS ANALYSIS OF THE USE OF COBLATION TECHNOLOGY VERSUS MECHANICAL DEBRIDEMENT IN KNEE CHONDROPLASTY - A UK NATIONAL HEALTH SERVICE PERSPECTIVE
    Adeyemi, A.
    Nherera, L.
    Trueman, P.
    VALUE IN HEALTH, 2018, 21 : S168 - S168
  • [5] Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective
    Hiligsmann, Mickael
    Williams, Setareh A.
    Fitzpatrick, Lorraine A.
    Silverman, Stuart S.
    Weiss, Richard
    Reginster, Jean-Yves
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (03) : 394 - 400
  • [6] A COST-EFFECTIVENESS ANALYSIS OF PREGABALIN VS. DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN CHINA
    Xie, X.
    Zhao, H.
    Liu, Z.
    Xiong, T.
    Liao, Q.
    VALUE IN HEALTH, 2019, 22 : S744 - S744
  • [7] COST-EFFECTIVENESS ANALYSIS OF AZACITIDINE VS. DECITABINE IN THE TREATMENT OF MYLODYSPLASTIC SYNDROMES IN CHINA
    Zhao, M.
    Chen, B.
    Wu, R.
    Fan, C. S.
    VALUE IN HEALTH, 2020, 23 : S46 - S46
  • [8] A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer's Perspective
    Nuijten, Mark
    Dainelli, Livia
    Rasouli, Bahareh
    Torres, Krysmaru Araujo
    Perugini, Moreno
    Marczewska, Agnieszka
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 3147 - 3160
  • [9] aPCC vs. rFVIIa for the Treatment of Bleeding in Patients with Acquired Hemophilia - a Cost-Effectiveness Analysis
    Kim, Chong H.
    Simmons, Sierra C.
    Bui, Chau M.
    Jiang, Ning
    Pham, Huy P.
    TRANSFUSION, 2018, 58 : 165A - 165A
  • [10] COST-EFFECTIVENESS ANALYSIS OF IXEKIZUMAB VS. SECUKINUMAB IN SEQUENTIAL BIOLOGIC TREATMENT OF PSORIASIS IN THE UK
    Johansson, E.
    Svedbom, A.
    Kumar, G.
    Hartz, S.
    Kiri, S.
    VALUE IN HEALTH, 2016, 19 (07) : A568 - A568
12345